AgomAb Therapeutics NV (NASDAQ:AGMB) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) have been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $33.00.

A number of equities research analysts have issued reports on AGMB shares. HC Wainwright assumed coverage on shares of AgomAb Therapeutics in a research report on Monday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company. B. Riley Financial initiated coverage on shares of AgomAb Therapeutics in a report on Thursday. They set a “buy” rating and a $34.00 price target on the stock.

AgomAb Therapeutics Stock Performance

NASDAQ:AGMB opened at $12.97 on Friday. The firm’s 50-day simple moving average is $11.75. AgomAb Therapeutics has a fifty-two week low of $8.75 and a fifty-two week high of $17.82.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.